How Do BCR::ABL1 Transcripts Affect CML Monitoring?

The specific type of BCR::ABL1 transcript you have—such as the common e13a2 and e14a2, or the rarer e1a2, e6a2, and e19a2—directly determines how your molecular tests must be designed and monitored ^[1]. Standard tests are built for the common transcripts, meaning patients with rare transcripts need customized testing to avoid false-negative results ^[2]. An “undetectable” result on an assay not designed for your specific transcript could give a false sense of security, so it is critical that your care team uses the right test ^[3].

Understanding Common vs. Rare Transcripts

In Philadelphia-chromosome positive chronic myeloid leukemia (CML), pieces of the BCR and ABL1 genes break and fuse together. The exact spot where they join can vary. This creates different versions of the fusion gene called transcripts. For example, the name “e13a2” (also known as b2a2) simply means that exon 13 of the BCR gene fused to exon 2 of the ABL1 gene.

Your exact transcript is identified at diagnosis. This is commonly done by identifying the Philadelphia chromosome through cytogenetics or FISH, followed by multiplex RT-PCR, and sometimes sequencing the gene to map out the exact fusion junction ^[3][2].

• The Common Transcripts (e13a2 and e14a2, or b2a2 and b3a2): The vast majority of people with CML have these forms. Standard PCR tests are specifically designed to look for them ^[1].
• The Rare (Atypical) Transcripts (e1a2, e6a2, e19a2): A small percentage of people have atypical junctions. Because routine screening tests are not designed to catch them, these rare transcripts can be missed ^[2].

How Your Transcript Affects Your Testing

Your transcript type dictates how your laboratory tracks your disease burden over time using RT-qPCR (quantitative polymerase chain reaction), a test that measures the amount of leukemia RNA in your blood.

Testing for Common Transcripts

If you have e13a2 or e14a2, your PCR results can generally be reported on the International Scale (IS), provided your testing is done by a suitably standardized laboratory ^[4]. The International Scale standardizes results across different laboratories so your doctor can apply standard clinical milestones ^[5].

For example, a Major Molecular Response (MMR) on the International Scale is defined as a BCR::ABL1 level of 0.1% or less ^[6]. Achieving these milestones guides your targeted therapy, usually involving a tyrosine kinase inhibitor (TKI). Typically, testing occurs every 3 months initially, then every 3-6 months once milestones are met.

The test relies on comparing your leukemia cells to a reference or control gene (like ABL1 or GUSB) ^[7]. The control gene ensures the sample quality is adequate and the test was sensitive enough to detect microscopic amounts of disease ^[4].

Testing for Rare Transcripts

If you have an atypical transcript (like e1a2, e6a2, or e19a2), your results generally cannot be reported on the International Scale because the IS is not validated for these forms ^[1]. Standard IS milestones like “0.1% MMR” do not apply.

Instead, laboratories must use customized, validated PCR primers or specialized techniques like digital PCR (ddPCR) designed specifically for your exact fusion ^[8]. Rather than using an international standard, your doctor will track how much your leukemia levels have dropped compared to a reliable baseline from before your treatment started. You might hear this referred to as a “log reduction” (a mathematical way of measuring a large drop) or an individualized response ^[1][9].

The Importance of Consistency

Fluctuating PCR numbers can be stressful, but small changes can simply reflect normal biological variation or laboratory differences rather than your leukemia getting worse ^[3]. Because of this, it is highly recommended to use the same laboratory consistently ^[9]. If you must change laboratories, provide the new lab with your original transcript details and ask if their method is comparable to your previous one. Also, never stop or change your medication based on a single PCR result without discussing it with your doctor.

Do Transcripts Affect Prognosis?

Different transcripts have been associated with slight differences in how the disease behaves, though these are just general, observational trends and not strict rules for any individual patient. Your actual response to treatment over time is far more informative than your transcript type.

• e14a2 vs e13a2: Some observational studies have shown that patients with the e14a2 transcript often achieve faster and deeper molecular responses than those with e13a2 ^[10]. e14a2 is also associated with a higher likelihood of maintaining a Treatment-Free Remission (TFR) ^[10][11]. However, TFR depends on maintaining a very deep molecular response for a long time, alongside strict clinical criteria. Your transcript type alone does not determine if you can safely stop your TKI. Furthermore, large studies show no significant long-term survival differences between e14a2 and e13a2 ^[12][13].
• Rare Transcripts (e1a2, e6a2, e19a2): The data on atypical transcripts is of lower certainty, coming mostly from small retrospective studies and case reports ^[14]. Some small studies suggest e1a2 and e19a2 might have lower TKI response rates, and e6a2 has occasionally been linked to more aggressive disease presentations ^[15][14]. However, there are also reports of patients with rare transcripts achieving excellent, deep responses to modern TKIs ^[16][17]. An atypical transcript does not by itself determine a poor outcome or dictate that you need a specific TKI.